IMCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IMCR is not a good buy right now for a beginner long-term investor. The stock is technically oversold, but the overall trend remains bearish, Wall Street sentiment has turned cautious, and there is no strong proprietary buy signal today. For an investor who is impatient and wants a clear entry now, this is not the best setup. I would avoid buying at this level and wait for a better confirmation of trend reversal or stronger catalyst support.
Pre-market price is 27.91, sitting just below the pivot at 29.687 and near S1 at 28.026, with S2 at 26.999 as the next notable support. Momentum is weak: MACD histogram is negative and expanding, RSI_6 is 19.501, which shows the stock is deeply oversold, but oversold alone does not confirm a reversal. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, confirming a downtrend. Short-term probability data suggests a modest bounce next day, but the broader trend still favors caution.
["Revenue in 2025/Q4 increased 24.30% YoY, showing continued top-line growth.", "RSI is deeply oversold, which can support a short-term bounce.", "Options positioning shows a lower put-call ratio of 0.41, suggesting some bullish sentiment.", "Historical pattern data points to a possible next-day rebound probability."]
["Jefferies downgraded IMCR to Hold from Buy and cut the target to $33 from $48, citing limited upside and risky pipeline dependence.", "No news in the past week, so there is no fresh catalyst driving the stock higher.", "Technical trend is bearish with MACD weakening and moving averages stacked negatively.", "Net income remains negative at -$30.06M in 2025/Q4, and EPS is still negative.", "Gross margin declined year over year.", "Hedge funds and insiders are both neutral, showing no strong accumulation signal.", "No recent congress trading data and no recent influential figure buying activity."]
In 2025/Q4, Immunocore posted revenue of $104.478M, up 24.30% YoY, which is a healthy growth trend. However, profitability remains weak with net income at -$30.06M and EPS at -0.59, even though both improved year over year. Gross margin stayed very high at 97.41% but declined 2.21% YoY. Overall, the latest quarter shows good revenue growth but continued losses, which is acceptable for a biotech company but not enough to justify an aggressive buy on its own.
Analyst sentiment has softened recently. On 2026-03-16, Jefferies downgraded IMCR to Hold from Buy and lowered its price target to $33 from $48, saying Kimmtrak is real but peak sales may be near and the pipeline is risky. On 2026-02-19, Mizuho raised its target slightly to $38 from $37 but kept a Neutral rating. The overall Wall Street view is cautious: the bull case is pipeline upside, while the bear case is that current product growth may be reaching a ceiling and the stock needs new execution to rerate.
